In hypertrophic cardiomyopathy (HCM), attempts to associate genotype with phenotype have largely been unsuccessful. More recently, cardiac magnetic resonance (CMR) imaging has enhanced myocardial fibrosis characterization, while nextgeneration sequencing (NGS) can identify pathogenic HCM mutations. We used CMR and NGS to explore the link between genotype and fibrotic phenotype in HCM.
Introduction
While hypertrophic cardiomyopathy (HCM) is defined by the presence of otherwise unexplained left-ventricular (LV) hypertrophy associated with non-dilated ventricular chambers, 1 precisely why the clinical manifestations and natural history of this condition are so diverse remains uncertain. Advances in non-invasive tissue characterization with contrastenhanced cardiac magnetic resonance (CMR) imaging have facilitated recognition of the importance of myocardial fibrosis in HCM. Late gadolinium enhancement (LGE) indicates a regional increase in myocardial collagen content, 2 and its presence and extent predict adverse outcomes. 3 However, LGE sequences cannot reliably evaluate the more diffuse patterns of myocardial fibrosis observed histologically in explanted hearts of HCM patients. 4 T 1 mapping is a novel technique to detect and quantify such diffuse myocardial fibrosis, and several methods have correlated with myocardial collagen content measured in histological specimens. 5, 6 Confirmation of a genetic basis for HCM was first described over two decades ago using linkage analysis 7 and, despite the subsequent identification of several disease-causing genes, 8 attempts to link genotype with phenotype have largely been unsuccessful. HCM patients possessing a recognized pathogenic HCM mutation are known to be younger at initial diagnosis, 9 exhibit more LV hypertrophy, 9 and are at a heightened risk of symptom progression and adverse cardiovascular outcomes, 10 however, clinically relevant associations with specific mutations have not been made. The development of next-generation sequencing (NGS) enables fast and cost-efficient testing of all known HCM genes to identify pathogenic mutations.
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In the present study, we performed a comprehensive evaluation of both diffuse and regional patterns of myocardial fibrosis in a typical cohort of HCM patients using contrast-enhanced CMR. Furthermore, we utilized NGS to explore links between genotype and phenotype in HCM.
Methods

Patient selection
All research was performed at the Alfred Hospital, Melbourne, Australia. One hundred and thirty-nine consecutive patients referred to our CMR department for the further evaluation of established asymmetric septal hypertrophy (ASH) or apical hypertrophy due to HCM were invited to participate. Asymmetric septal hypertrophy was defined as a maximum interventricular septum thickness ≥15 mm with a ratio of septal-tolateral LV wall thickness of ≥1.3:1.0, while apical hypertrophy was defined as LV apical wall thickness ≥12 mm. Diagnosis of HCM required the absence of another condition that could cause the degree of hypertrophy observed. 1 Twenty-five asymptomatic subjects without cardiovascular disease or a family history of HCM formed a healthy control group. Exclusion criteria included prior septal reduction therapy, coronary artery disease, chronic atrial fibrillation, contraindications to CMR, including pacemaker and defibrillator implantation, and significant renal dysfunction [estimated glomerular filtration rate (eGFR) , 50 mL/min/ 1.73 m 2 ]. Informed consent was obtained from all participants and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the Alfred Hospital Ethics Committee's guidelines.
CMR protocol
We performed CMR on all patients using a clinical 1.5-T scanner (Signa HD 1.5-T, GE Healthcare, Waukesha, WI, USA). All sequences were acquired during breath-holds of 10 -15 s. Initially, a contiguous shortaxis steady-state free precession cine stack [repetition time [TR] ¼ 3.8 ms, echo time [TE] ¼ 1.6 ms, 30 phases] was acquired, extending from the mitral valve annulus to the LV apex (8 mm slice thickness, no gap), to enable volumetric analysis of the LV using the summation of disc method.
Late gadolinium enhancement was evaluated 10 min after a bolus of gadolinium-diethylene triamine penta-acetic acid (DTPA) (0.2 mmol/ kg BW Magnevist, Schering, Germany) to identify regional myocardial fibrosis using a T 1 -weighted inversion recovery gradient echo technique [TR 7.1 ms, TE 3.1 ms, inversion time [TI] individually determined to null the myocardial signal, 8 mm slice thickness, acquisition matrix 256 × 192, number of acquisitions 2, inversion pulse every RR interval]. To enable accurate nullification of healthy myocardium, a TI optimization sequence was performed 8 min post-gadolinium administration with a fast gradient echo, inversion recovery, gated, multiphase acquisition, commencing at an inversion time of 150 ms, and increasing in 25 ms increments to 250 ms, in a mid-ventricular shortaxis slice.
LGE imaging was performed using standard long-axis views of the LV and a contiguous short-axis stack from the mitral valve annulus to the LV apex. Regional fibrosis was identified by LGE within the myocardium, defined quantitatively by a myocardial post-contrast signal intensity 6 SD above that within a reference region of remote myocardium (without LGE) within the same slice. 12, 13 Late gadolinium enhancement quantity, expressed as a percentage of total LV mass, was calculated from all short-axis slices using the summation of disc method.
To evaluate diffuse myocardial fibrosis, a histologically validated post-contrast T 1 mapping sequence was used to cycle through acquisition of images obtained at an LV short-axis level over a range of inversion times, as described previously. 6 This adiabatic electrocardiogram-triggered, inversion recovery prepared, 2-dimensional fast gradient echo sequence employed variable temporal sampling of k-space (VAST) 14 (GE Healthcare). Ten images at the basal, mid, and apical LV short-axis levels were acquired sequentially at increasing inversion times, commencing 20 min after the bolus of gadolinium-DTPA (TI range 75 -750 ms), and each over a series of 3 -5 breathholds using the following imaging parameters: TR 3.7 ms, TE 1.2 ms, 208 flip angle, 256 × 128 acquisition matrix, 36 × 27 cm field of view, 1.4 × 2.1 mm in plane resolution, 8 mm slice thickness, trigger delay 300 ms (2 R-R intervals were utilized if the trigger delay plus preparation pulse delay was longer than one R-R interval, and the trigger delay was reduced if the trigger delay plus preparation pulse delay was longer than two R-R intervals), and views per segment 24. In contrast to the commonly used Modified Look-Locker inversion recovery (MOLLI) technique, each preparation pulse was followed by a single readout phase to acquire each of the 10 images. Following acquisition, images were transferred to an external computer for analysis using a dedicated research software package with a curve fitting technique to generate T 1 maps (Cinetool, GE Healthcare).
For each short-axis image, a region of interest (ROI) was manually drawn around the entire LV myocardium (excluding regions of LGE by visual assessment) to calculate post-contrast myocardial T 1 time ( Figure 1) . Post-contrast myocardial T 1 time was derived by calculating the mean T 1 time of all three short-axis levels. To account for the potential effects of renal function and time delay between contrast administration and image acquisition on gadolinium pharmacokinetics, correction values 15 were used to normalize post-contrast myocardial T 1 times to a matched state (eGFR ¼ 90 mL/min/1.73 m 2 ,
time from contrast administration to image acquisition ¼ 20 min) for all three short-axis levels. To investigate the association between post-contrast myocardial T 1 time and the myocardial collagen content of septal myectomy specimens (see Histology), identical T 1 mapping methodology was used; however, the ROI was selected to include the likely site of surgical excision within the basal interventricular septum.
Evaluation of myocardial fibrosis in HCM with CMR imaging
Histology
In a subgroup of patients with HCM who underwent septal myectomy within 4 weeks following CMR, histological quantification of myocardial collagen content was performed using surgically obtained specimens. Myectomy tissue specimens were fixed immediately in 10% buffered formalin, embedded in paraffin, routinely processed, and stained with picrosirius red to obtain contrast between myocardium and areas of collagen ( Figure 2 ). At least 30 digital images per patient at 100× magnification were acquired from all myectomy specimens, with subendocardial and perivascular areas excluded from further analysis. An automated image analysis protocol (using an ImageJ macro 16 ) determined myocardial collagen content, with myocardial collagen area expressed as a percentage of total myocardial area for each patient.
Echocardiography protocol
Echocardiography with a standard clinical protocol was performed immediately prior to CMR. Diastolic function was assessed by a combination of mitral inflow pattern (E to A ratio) and early mitral annular velocities (e ′ , measured at the septal and lateral aspects of the mitral annulus in the apical 4-chamber view). Mitral E/e ′ was chosen as an index of LV diastolic function. In all subjects, peak LV outflow tract (LVOT) pressure gradients were measured with pulse wave Doppler both at rest and during Valsalva provocation. All measurements were made in accordance with the American Society of Echocardiography guidelines. 17 
HCM genetic mutation detection
A subgroup of HCM patients underwent clinical genetic testing after CMR for a panel of 65 cardiac disease genes using massively parallel sequencing approach on lymphocyte-derived DNA. Thirty-six genes associated with HCM were included in a targeted exon capture array (NimbleGen capture array or Agilent Sure Select), with the products sequenced on an Illumina HiSeq platform. All low-coverage regions (,15×) were re-sequenced by Sanger-sequencing. Data analysis was performed with a custom bioinformatics pipeline, 18 including the tools GATK for alignment, ANNOVAR 19 for annotation of variants and in-house scripts for analysis of splice effects. Variants were classified into five classes, including pathogenic or likely pathogenic mutations, based on an algorithm that incorporates reference to previous publications, locus specific databases, large population sequencing databases (dbSNP, 1000 Genomes, NIH Exome Variant Server), in-silico analysis of evolutionary conservation and physicochemical effects (GERP score, PhyloP, SIFT, Polyphen2, A_GVGD) and any available functional data. 
Image analysis
CMR and echocardiographic images were interpreted by two experienced readers unaware of the subjects' clinical information and other 
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diagnostic test results. Endocardial and epicardial LV contours were drawn manually for each diastolic and systolic frame, excluding papillary muscles. CMR LV volumetric and LGE analysis was performed on a GE Healthcare Advantage Workstation 4.2 using ReportCARD 3.6 software.
Statistical analysis
All data are expressed as mean + standard deviation (SD) unless otherwise indicated. For all comparisons, a P-value of ,0.05 was considered significant, and all reported P-values are 2-tailed. Comparison of normally distributed variables utilized the unpaired Student's t-test; of nonparametric data, the Wilcoxon -Mann-Whitney test; and, of categorical data, the x 2 test. Correlations of variables were determined by calculating the Pearson Product Moment. Multiple linear regression was used to determine the independence of correlations observed on simple linear regression, with all correlations with a P-value ,0.10 entered into multiple linear regression analysis. Binary categorical variables were entered into the analyses using dummy coding. T 1 times were compared across groups using a one-way analysis of variance (ANOVA) with post hoc testing (Holm-Sidak method) to correct for multiple comparisons. All analyses were conducted using Stata software version 11.1 (StataCorp, College Station, TX, USA).
Results
Subject characteristics
A total of 139 patients with HCM from 133 unrelated families, and 25 healthy control subjects were included during the study period. General characteristics of both groups are presented in Table 1 . The HCM and control groups had similar age, heart rate, systolic blood pressure, haematocrit, and eGFR, while the HCM group had significantly higher body mass index (BMI, 28.1 + 5.2 vs. 24.1 + 2.7 kg/m 2 , P , 0.001).
Histological validation of post-contrast T 1 mapping in HCM
Septal myectomy was performed in nine HCM patients. Mean myocardial collagen content of myocardial specimens was 12.8 + 5.3%. A significant correlation between post-contrast myocardial T 1 time and myocardial collagen content was observed (r ¼ 20.70, P ¼ 0.03) ( Figure 3 ). Late gadolinium enhancement was not observed within the ROIs defining the presumed sites of surgical excision.
CMR and echocardiography data
CMR and echocardiography results are displayed in Table 2 . CMR was completed in all patients and complete echocardiography results were available in 125 patients. Patients with HCM had higher LV ejection fraction (LVEF, 69 + 7 vs. 60 + 6%, P , 0.001) and LV mass indexed to BSA (85 + 30 vs. 52 + 9 g/BSA, P , 0.001) and their maximum wall thickness was 20 + 4 mm. Interpretable LGE images were obtained in 161 (98%) subjects. Late gadolinium enhancement was observed in 117 (86%) HCM patients and accounted for 4.6 + 6.1% of LV mass. When present, LGE was most commonly observed at the point(s) of right-ventricular wall insertion (68%) or within the interventricular septum (44%). No patient demonstrated an ischaemic pattern of LGE.
T 1 mapping image quality was sufficient for analysis in 486 (99%) of 492 LV short-axis slices. Post-contrast myocardial T 1 time was significantly lower in HCM patients than healthy controls (483 + 83 vs. 545 + 49 ms, P , 0.001) (Figure 4) . Post-contrast T 1 time of the LV blood pool was similar between both groups (308 + 49 vs. Evaluation of myocardial fibrosis in HCM with CMR imaging 306 + 22 ms, P ¼ 0.8), excluding altered contrast kinetics as a potential confounder to the observed differences in myocardial postcontrast T 1 times.
Factors associated with extent of LGE in HCM group
Significant correlations were observed between the extent of LGE and both LVEF (r ¼ 20.52, P , 0.001) and peak LVOT pressure gradients (r ¼ 20.32, P ¼ 0.02), but not with E/e ′ (r ¼ 0.14, P ¼ HCM patients with a mutation also had significantly lower LVEF and peak LVOT pressure gradient and a trend toward lower E/e ′ ( Table 4) .
CMR indices of regional and diffuse myocardial fibrosis differed according to HCM mutation status. Late gadolinium enhancement was observed in a greater proportion of G+ HCM patients than those without mutations (94 vs. 68%, P , 0.01), and LGE quantity was also significantly higher (7.9 + 8.6 vs. 3.1 + 4.3%, P ¼ 0.03). Surprisingly, G+ HCM patients had higher post-contrast myocardial T 1 times compared with those without mutations (498 + 81 vs. 451 + 70 ms, P ¼ 0.03), suggestive of less diffuse myocardial fibrosis in HCM patients with a recognized HCM mutation ( Figure 5 ). When areas of LGE were included in the ROIs for post-contrast T 1 mapping, this significant difference was maintained (489 + 92 vs. 436 + 57 ms, P ¼ 0.02).
Linking specific HCM mutations with phenotype
There were no significant differences in CMR or echocardiographic data according to specific HCM mutations. Specifically, G+ HCM patients with MYBPC3 or MYH7 mutations had similar LV dimensions, LGE quantity and location, and post-contrast T 1 times ( Table 5) .
Discussion
We performed a comprehensive evaluation of both diffuse and regional patterns of myocardial fibrosis in a cohort of patients with HCM using contrast-enhanced CMR, and investigated links between genotype and phenotype. Compared with healthy subjects, those with HCM manifest lower post-contrast myocardial T 1 times, suggestive of more diffuse myocardial fibrosis, and a greater quantity of LGE, consistent with more regional myocardial fibrosis. Furthermore, HCM patients with an identifiable genetic mutation had evidence of significantly more regional, but less diffuse, myocardial fibrosis, than patients without mutations. We did not demonstrate significant associations between individual HCM mutations and specific phenotypic characteristics.
What is the clinical significance of lower post-contrast myocardial T 1 times? HCM patients with dyspnoea had significantly lower T 1 times than those without breathlessness, and T 1 time correlated with both myocardial collagen content by histological analysis and estimated LV filling pressures by echocardiography. To our knowledge, this is the first study to document a link between abnormal T 1 myocardial signal, impaired LV physiology, and clinical symptoms in this patient group. Multiple studies performed by independent centres 5, 6 have shown significant correlations between post-contrast T 1 time and the amount of fibrosis in human myocardial biopsy specimens. More diffuse myocardial fibrosis may result in increased passive LV stiffness, which contributes to diastolic dysfunction and resultant symptoms of dyspnoea. In a cohort of cardiac transplant recipients, we recently demonstrated a significant correlation between postcontrast myocardial T 1 time and invasively determined LV stiffness. 21 Further investigation using LV pressure-volume measurements, both at rest and with exercise, may support this hypothesis in patients with HCM. Whether post-contrast myocardial T 1 times also provide prognostic information will also be determined. We found no association between post-contrast T 1 time and the presence or quantity of LGE. This differs from findings by Ho et al. 22 in which they found both a correlation between extracellular volume fraction (ECV) and LGE extent, and a higher ECV, suggestive of more diffuse fibrosis, in HCM patients with sarcomere mutations compared with healthy controls. There are several explanations for these differences. Firstly, the present study's HCM cohort was older and more symptomatic, had a lower proportion of MYBPC3 mutations but more MYH6 mutations, and had a higher number of G2 HCM patients. Secondly, varying T 1 mapping methods and sequences characterize myocardial tissue differently. In the present study, we provided further histological validation of our VAST T 1 mapping technique in HCM. MOLLI sequences are sensitive to T 2 , imaging parameters and heart rate, in addition to T 1 changes, due to the effect of multiple readouts following a single preparation pulse. 23, 24 Also, while MOLLI sequences rely on the mathematical conversion of the measured T 1 * to obtain a true T 1 value, 'single point' T 1 mapping sequences, such as the one employed in our study, measure true T 1 and are generally not sensitive to such T 2 effects. Lastly, in our genotype status comparison, all but one patient had multiple short-axis LV levels available to calculate T 1 time, whereas only a single mid-LV short-axis slice was used for T 1 mapping analysis in 18 patients of Ho et al.'s cohort reportedly due to technical difficulties. HCM patients with an identifiable mutation had evidence of significantly less diffuse myocardial fibrosis than patients without such a mutation and, supporting the link between T 1 time and diastolic function, also had significantly less dyspnoea and a trend towards lower estimated LV filling pressures. However, these same patients had .... ...... ...... ...... ..... ...... ...... ...... ...... ...... ...... ...... ... .. ... more regional myocardial fibrosis by LGE. Extent of LGE is a predictor of ventricular arrhythmia and sudden cardiac death in HCM 3 and, after medium-term follow-up, the presence of a pathogenic mutation has been associated with an increased risk of a combined endpoint that included cardiovascular death. 10 Increased quantities of LGE, reflective of more regions of potentially arrhythmogenic dense myocardial fibrosis, in our patients with pathogenic HCM mutations, may contribute to the worse prognosis previously observed in this subgroup. Long-term follow-up may strengthen this putative association. The capability to non-invasively identify and measure separate patterns of myocardial fibrosis with distinct clinical implications has the potential to improve the management of this complex condition.
For example, HCM patients with lower post-contrast myocardial T 1 times may benefit from targeted therapies aimed at regressing diffuse myocardial fibrosis, which may improve LV diastolic dysfunction. For patients with large quantities of LGE, an implantable cardioverterdefibrillator may be indicated for primary prophylaxis against ventricular arrhythmia and sudden death.
Despite our use of the latest cardiac imaging and genetic testing technologies, linking a specific genetic mutation with a particular phenotype remains elusive in HCM. Our HCM patients had comparatively thicker LV walls and a higher LGE prevalence than previously studied cohorts, yet only 64% exhibited an identifiable pathogenic mutation. After comparing patients with mutations in the most commonly identified genes, MYBPC3 and MYH7, no significant phenotypic differences were observed. NGS enables faster, less expensive, and more comprehensive genetic testing than previous techniques and is likely to make the rapid assessment of larger numbers of HCM patients simpler and more cost-effective. However, determining which mutations are actually pathogenic will become increasingly challenging. We identified mutations currently classified as VUS in several patients. With co-segregation analysis, some of these VUS mutations may be reclassified as pathogenic and this could assist in better elucidating the roles of genetic and environmental factors in influencing phenotype. Also of importance will be the further study of G+ family members without LV hypertrophy, but who exhibit structural abnormalities, such as myocardial crypts, diastolic impairment, and LGE. 25, 26 Limitations Hypertrophic cardiomyopathy patients with a defibrillator and at highest risk of sudden death were not included in this study.
Further validation of T 1 mapping methods with myocardial tissue is necessary. Research correlating post-contrast T 1 mapping with myocardial fibrosis is limited by small patient numbers and limited specimens obtained by either endomyocardial biopsy 5, 6 or surgical myectomy. 27 However, acquiring whole hearts for detailed collagen content quantification will remain difficult. Post-contrast T 1 times can be influenced by non-fibrotic myocardial tissue processes, such as myocardial oedema, and factors relating to gadolinium contrast pharmacokinetics, including dose of contrast, time from contrast administration to T 1 measurement, equilibrium kinetics, and renal clearance. In the present study, T 1 times were corrected for both eGFR and duration of time between contrast administration and image acquisition. While the development of this correction model 15 was limited by the absence of subjects with significant renal insufficiency, all participants in the present study had preserved renal function (ie. eGFR ≥50 mL/min/1.73 m 2 ). Furthermore, there were no significant differences in theoretical confounders of post-contrast T 1 time, such as haematocrit and heart rate, between the comparison groups and LV blood pool T 1 times did not significantly differ. ECV, an alternative method of extracellular matrix expansion quantification which incorporates native (pre-contrast) myocardial T 1 signal, blood pool T 1 time, and haematocrit, 28 was not performed in the current study as these methods had not been published at the time of study inception.
Conclusions
In HCM, contrast-enhanced CMR with T 1 mapping can noninvasively evaluate both regional and diffuse patterns of myocardial fibrosis. Greater quantities of LGE, consistent with more regional myocardial fibrosis, are associated with reduced LV systolic function and less outflow tract obstruction, whereas patients with lower postcontrast T 1 times, indicative of more diffuse myocardial fibrosis, have more LV diastolic impairment and symptoms of dyspnoea. Hypertrophic cardiomyopathy patients with an identifiable mutation have significantly more regional, but less diffuse myocardial fibrosis than those without. Further research utilizing advanced tissue characterization techniques and NGS may identify links between specific pathogenic mutations and particular HCM phenotypes and facilitate more individualized management strategies. 
